Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany

Abstract Background Overuse of short-acting beta-2 agonists (SABA), which do not treat the underlying inflammation of asthma, is linked to poor clinical outcomes such as increased exacerbation risk. This study, as part of the SABINA program, estimated the prevalence of SABA overuse and associated variables in outpatients in Germany. Methods This retrospective study used anonymized electronic healthcare data from the Disease Analyzer database (IQVIA). A total of 15,640 patients aged ≥ 12 years with asthma who received ≥ 1 SABA prescription(s) between July 2017 and June 2018 in 924 general physi... Mehr ...

Verfasser: Heinrich Worth
Carl-Peter Criée
Claus F. Vogelmeier
Peter Kardos
Eva-Maria Becker
Karel Kostev
Ingo Mokros
Andrea Schneider
Dokumenttyp: Artikel
Erscheinungsdatum: 2021
Reihe/Periodikum: Respiratory Research, Vol 22, Iss 1, Pp 1-8 (2021)
Verlag/Hrsg.: BMC
Schlagwörter: Asthma / Short-acting beta agonists / Overuse / GINA / Risk factors / Germany / Diseases of the respiratory system / RC705-779
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26894809
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1186/s12931-021-01701-3